# A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE

Source: https://onco.cc/trials/nct02411448/  
OnCo record `nct02411448` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ramucirumab, Erlotinib, Gefitinib in non-small-cell lung cancer and small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) is a phase 3 interventional study registered as NCT02411448 by Eli Lilly and Company, with 545 participants enrolled, started 2015-05-06 and due to reach its primary completion in 2019-01-23. Interventions recorded: Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib. Conditions listed: Metastatic Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2020; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: RELAY
- Tags: ctgov-ingest
- Registry id: NCT02411448
- Phase: 3
- Setting: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
- Sponsor: Eli Lilly and Company
- Enrolled: 545
- Outcomes: Part B: Progression Free Survival (PFS): Part B: Ramucirumab+ Erlotinib 19.4 months vs Part B: Placebo+ Erlotinib 12.4 months, HR 0.591; Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]): Part B: Ramucirumab+ Erlotinib 76.3% vs Part B: Placebo+ Erlotinib 74.7%

## Sources

- ClinicalTrials.gov NCT02411448: https://clinicaltrials.gov/study/NCT02411448

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Erlotinib](https://onco.cc/drugs/erlotinib/), [Gefitinib](https://onco.cc/drugs/gefitinib/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)
- key papers: [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://onco.cc/key-papers/paper-nct02411448-lancet-oncol-2019/), [RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC](https://onco.cc/key-papers/paper-nct02411448-j-thorac-oncol-2025-update/)

---
JSON: https://onco.cc/api/v1/entities/nct02411448.json